Clinical Trials Browser

Completed × cediranib × Clear all

NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase 2 Completed

34 enrolled 22 charts

Sarcoma, Alveolar Soft Part

NCT00942877 2025-03-03

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Phase 2 Completed

53 enrolled 17 charts

Sarcoma, Sarcoma, Alveolar Soft Part

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

NCT03117933 2024-01-23

OCTOVA

Phase 2 Completed

Ovarian Neoplasms

NCT00795340 2023-08-22

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3 Completed

306 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00107250 2023-08-04

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00245154 2023-08-04

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00343408 2023-08-04

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT01062425 2022-07-26

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Completed

261 enrolled 10 charts

Glioblastoma, Gliosarcoma

NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Phase NA Completed

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

Phase 2 Completed

62 enrolled 15 charts

Ovarian Neoplasms

NCT02855697 2022-02-22

MOLTO

Phase EARLY_PHASE1 Completed

Ovarian Neoplasms

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Phase 1/2 Completed

127 enrolled 18 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT01065662 2021-04-21

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

Phase 1 Completed

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00321581 2019-11-21

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Phase 1 Completed

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01132820 2019-08-08

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

53 enrolled 11 charts

Endometrial Adenocarcinoma

NCT00436956 2018-10-09

AZD2171 to Treat Prostate Cancer

Phase 2 Completed

59 enrolled 12 charts

Prostatic Neoplasms

NCT00278343 2018-08-29

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2 Completed

74 enrolled 11 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00243061 2018-08-27

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Phase 2 Completed

24 enrolled 12 charts

Uveal Melanoma, Melanoma

NCT01260688 2018-08-08

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Phase 2 Completed

22 enrolled 23 charts

Prostatic Neoplasms

NCT00410904 2018-04-13

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Phase 2 Completed

60 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00243074 2018-01-23

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Phase 2 Completed

54 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00384176 2017-04-14

HORIZON III

Phase 2/3 Completed

1,814 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT00326599 2017-03-21

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

101 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00475150 2017-02-15

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2 Completed

39 enrolled 9 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00399035 2016-12-28

HORIZON II

Phase 3 Completed

1,254 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT00777153 2016-12-28

REGAL

Phase 3 Completed

423 enrolled 13 charts

Glioblastoma, Neoplasms

NCT00454805 2016-08-03

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Phase 2 Completed

75 enrolled 11 charts

Advanced Breast Cancer

NCT00326664 2016-03-07

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase 1 Completed

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

NCT00227760 2016-02-29

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

44 enrolled 8 charts

Carcinoma, Renal Cell

NCT00244881 2015-12-07

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Phase 2 Completed

26 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00275028 2015-11-09

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

47 enrolled 15 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00458978 2015-05-05

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00979862 2015-04-15

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

NCT00939848 2014-10-27

ABC-03

Phase 2/3 Completed

Gastrointestinal

Biliary Tract Neoplasms

NCT00245063 2014-10-02

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Completed

25 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung

NCT00621725 2014-07-15

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Phase 1 Completed

Neoplasm Metastasis

NCT00494221 2014-03-27

A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

Phase 1/2 Completed

172 enrolled 12 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Phase 1 Completed

LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Phase 1 Completed

19 enrolled 7 charts

Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT01229930 2013-08-26

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

Uterine Cervical Neoplasms

NCT00305656 2013-08-22

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00238394 2013-06-05

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT00321724 2013-01-15

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00621361 2012-12-17

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Phase 1 Completed

Lung Neoplasms

NCT00306891 2012-11-01

Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)

Phase 2 Completed

60 enrolled 13 charts

Neoplasms

NCT00278889 2012-10-24

HORIZON I

Phase 2 Completed

215 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms